Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

CMR International

Centre for Medicines Research. Describing Dossiers Characterising Clinical Dossiers for Global Registration. R D Briefing 25, CMR International, Surrey, UK, 2000. [Pg.569]

Centre for Medicines Research http //www.cmr.org, Innovation on the wave CMR International, 2004. [Pg.134]

CMR International. Global clinical performance metrics programme. (Internet at www.cmr.org see "CMR Programs.")... [Pg.437]

Spence, C., ed. 1997. The pharmaceutical R D compendium CMR International/SCRIP s guide to trends in R D. Richmond, Survey, UK CMR International/SCRIP Publication. [Pg.11]

CMR International (2007). The CMR International 2007 Pharmaceutical R D Faetbook. CMR International. http //cmr. thomsonreuters. com/services/faetbook... [Pg.39]

Company strategies for designing non-clinical safety evaluation programmes Results of a CMR International survey... [Pg.19]

Companies were asked to provide information on general strategies for designing safety evaluation programmes for products of biotechnology and, in addition, to provide information on the type of studies conducted for specific product classes with which they had experience, up to a maximum of two per respondent. The type of information requested reflected the concerns of the industry which were identified in a previous CMR International... [Pg.21]

Griffiths SA, Ashton GA and Lumley CE (1995). Non-clinical Safety Testing of Products of Biotechnology Issues of Concern. CMR International Report, CMR95-63R, December 1995. [Pg.31]

The ICH guideline on preclinical safety evaluation of biotechnologically-derived pharmaceuticals has recently achieved Step 4 of the ICH process. This represents a success for harmonisation and it will be important to assess the impact of these guidelines on the development of biotechnology-derived pharmaceuticals. However, it will be necessary to continue to re-examine what new data may be necessary to assess the safety of biotechnologically-derived products and to identify new issues that need to be addressed. The CMR International workshop has made a significant contribution along these lines. [Pg.213]

In 2000, CMR International estimated that, on a global basis, pharmaceutical companies invested U.S. 58 billion in R D, an increase... [Pg.48]

Kermani, F., Findlay, G. The Pharmaceutical R D Compendium CMR International/Scrip s Complete Guide to Trends in R D. CMR Intemational/SCRIP Publication http //www.cmr.org/ (accessed November 1,2005)... [Pg.104]

See other pages where CMR International is mentioned: [Pg.118]    [Pg.342]    [Pg.12]    [Pg.48]    [Pg.922]    [Pg.749]    [Pg.921]    [Pg.42]    [Pg.1]    [Pg.2]    [Pg.21]    [Pg.49]    [Pg.129]    [Pg.189]    [Pg.190]    [Pg.190]    [Pg.191]    [Pg.191]    [Pg.192]    [Pg.204]    [Pg.209]    [Pg.213]    [Pg.214]    [Pg.216]   


SEARCH



CMRs

© 2024 chempedia.info